Skip to content
10-Q

Quarterly Report

Syndax Pharmaceuticals, Inc. SNDX

0000950170-25-063518

← back to feed
Filed
May 5, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · May 1, 2025 86.05M sh
Short Term Debt Q1 2025 · Mar 31, 2025 $343.79M
Short Term Debt Q1 2025 · Dec 31, 2024 $343.68M
Short Term Investments Q1 2025 · Mar 31, 2025 $358.2M
Short Term Investments Q1 2025 · Dec 31, 2024 $418.8M
Cash And Equivalents Q1 2025 · Mar 31, 2025 $153.99M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $154.08M
Current Liabilities Q1 2025 · Mar 31, 2025 $94.55M
Current Liabilities Q1 2025 · Dec 31, 2024 $103.55M
Total Liabilities Q1 2025 · Mar 31, 2025 $425.65M
Total Liabilities Q1 2025 · Dec 31, 2024 $436.69M
Current Assets Q1 2025 · Mar 31, 2025 $548.75M
Current Assets Q1 2025 · Dec 31, 2024 $603.06M
Total Assets Q1 2025 · Mar 31, 2025 $640.71M
Total Assets Q1 2025 · Dec 31, 2024 $724.82M
Shares Diluted Q1 2025 · Mar 31, 2024 85.21M sh
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$83.55M
Stockholders Equity Q1 2025 · Mar 31, 2024 $491.89M
Stockholders Equity Q1 2025 · Dec 31, 2023 $554.2M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.85
Eps Basic Q1 2025 · Mar 31, 2024 −$0.85
Rd Expense Q1 2025 · Mar 31, 2024 $56.49M
Net Income Q1 2025 · Mar 31, 2024 −$72.4M
Operating Income Q1 2025 · Mar 31, 2024 −$79.51M
Revenue Q1 2025 · Mar 31, 2024 $0